ARTBIO inks exclusive deal with 3BP to grow radioligand pipeline

USA-based ARTBIO, a radiopharma firm working on alpha radioligand therapies, has entered a global licensing and research partnership with Berlin-based 3B Pharmaceuticals (3BP).

The deal grants ARTBIO exclusive rights to develop a peptide-based radioligand therapy targeting solid tumors, marking an expansion from its initial prostate cancer focus.

The partnership brings a first-in-class approach by targeting a novel peptide with potential applications across multiple solid tumor types. Scientists believe lead-212 will offer the potential to deliver high-energy doses precisely to tumor cells.